Pharmacyclics Management Discusses Q4 2012 Results - Earnings Call Transcript Seeking Alpha This is Phase III study of ibrutinib in combination with bendamustine/rituximab in patients with relapsed or refractory CLL or SLL. This is a randomized, multicenter Phase III, double-blinded, placebo-controlled registration trial of ibrutinib in ... |
